Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

The Phase 3 ICONIC clinical development program includes studies evaluating icotrokinra in moderate to severe plaque psoriasis (PsO) and psoriatic arthritis. ICONIC-LEAD and ICONIC-TOTAL are randomized controlled trials assessing safety and efficacy, with other studies ongoing.